Table 1 Patients’ characteristics
Early disease (24 patients) | Metastatic disease (37 patients) | ||
|---|---|---|---|
Age | N | Age | N |
  Median, range | 52 (37–72) |   Median, range | 59 (34–86) |
Menopausal status | Â | Menopausal status | Â |
  Premenopausal | 9 (37.5 %) |   Premenopausal | 11 (29.7 %) |
  Postmenopausal | 14 (58.3 %) |   Postmenopausal | 22 (59.5 %) |
  Unknown | 1 (4.2 %) |   Unknown | 4 (10.8 %) |
Tumor size | Â | Disease sites | Â |
  pT1 | 6 (25 %) |   1 | 15 (40.5 %) |
  pT2 | 8 (33.3 %) |   2 | 8 (21.6 %) |
  pT3 | 1 (4.1 %) |   3 | 5 (13.5 %) |
  Unknown | 9 (37.5 %) |   ≥4 | 3 (8.2 %) |
|  |  |   Unknown | 6 (16.2 %) |
Lymph node status | Â | Predominantly visceral disease | |
  Node-negative | 10 (41.7 %) |   Yes | 15 (40.5 %) |
  Node-positive | 10 (41.7 %) |   No | 17 (46 %) |
  Unknown | 4 (16.6 %) |   Unknown | 5 (13.5 %) |
Histologic grade | Â | Primary breast cancer | Â |
  Grade 1 | 0 (0 %) |   Adjuvant | 13 (35.1 %) |
  Grade 2 | 10 (41.7 %) |   Metastatic | 6 (16.2 %) |
  Grade 3 | 9 (37.5 %) |   Unknown | 18 (48.7 %) |
  Grade 4 | 2 (8.3 %) |  |  |
  Unknown | 3 (12.5 %) |  |  |
ER/PR tumor status | Â | ER/PR tumor status | Â |
  Positive | 20 (83.3 %) |   Positive | 22 (59.5 %) |
  Negative | 1 (4.2 %) |   Negative | 11 (29.7 %) |
  Unknown | 3 (12.5 %) |   Unknown | 4 (10.8 %) |
HER2 tumor status | Â | HER2 tumor status | Â |
  Positive | 5 (20.8 %) |   Positive | 16 (43.2 %) |
  Negative | 17 (70.8 %0 |   Negative | 17 (46 %) |
  Unknown | 2 (8.4 %) |   Unknown | 4 (10.8 %) |